Industry / United States
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
GSK Parkinson's Disease Drug Receives Approval
June 2008 | Product LaunchSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Despite the registration of a new medicine, the burden of Parkinson's disease in the US will continue to grow through to 2030. UK firm GlaxoSmithKline (GSK)'s Requip XL (extended-release ropinirole) is the first once-daily dopamine agonist to be sanctioned by the US FDA, but it is BMI's view that its impact on the disabling condition will be minimal. This is in part due to the product's marginal advantage over regular Requip, but mainly due to more people being diagnosed with the disease, itself due to the ageing of the baby boomer generation.